Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS status and epidermal growth factor receptor expression as determinants for anti-EGFR therapies in salivary gland carcinomas.

Oral oncology - 1 Sept 2009

Dahse Regine, Driemel Oliver, Schwarz Stephan, Kromeyer-Hauschild Katrin, Berndt Alexander, Kosmehl Hartwig

Abstract excerpt

Salivary gland carcinomas (SGC) are rare cancers with poor prognosis and limited response to conventional chemotherapy. New strategies based on molecular targeted therapy are needed and the EGFR signaling cascade is considered a possible key pathway for therapeutic molecules. We have analyzed 65 SGC of the main histopathological types for the expression of EGFR and and the mutation status of its downstream...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Carcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to KRAS gene

Share to Genes, ras

Share to Mutation

Share to Neoplasm Proteins

Share to Salivary Gland Neoplasms

Source

Identifiers

PMID: 19362042
DOI: 10.1016/j.oraloncology.2009.01.013

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS status and epidermal growth factor receptor expression as determinants for anti-EGFR therapies in salivary gland carcinomas.PMID 19362042Read ↗

Phosphorylated epidermal growth factor receptor expression and KRAS mutation status in salivary gland carcinomas.Semantic proximity Read ↗

Epidermal growth factor receptor (EGFR) in salivary gland carcinomas: potentials as therapeutic target.Semantic proximity Read ↗

Salivary gland carcinoma: Towards a more personalised approach.Semantic proximity Read ↗

Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype.Semantic proximity Read ↗

No incidence of BRAF mutations in salivary gland carcinomas--implications for anti-EGFR therapies.Semantic proximity Read ↗

Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours.Semantic proximity Read ↗

Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity.Semantic proximity Read ↗

[Salivary gland cancer: new therapeutic approaches].Semantic proximity Read ↗

Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas.Semantic proximity Read ↗

Targeting human EGFR 2 (HER2) in salivary gland carcinomaSemantic proximity Read ↗

Salivary Gland Cancers: Biology and Molecular Targets for TherapySemantic proximity Read ↗

Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.